Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Preparing compound containing a carotene nucleus
Patent
1995-10-31
1998-12-29
Lilling, Herbert J.
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Preparing compound containing a carotene nucleus
4352521, 435280, 435850, 426 61, 426250, 514729, C12P 2300
Patent
active
058540156
ABSTRACT:
A method is disclosed for making the 3R-3'R stereoisomer of zeaxanthin as a sole detectable or heavily dominant (more than about 90%) stereoisomer, for human ingestion. Zeaxanthin, a yellowish pigment which is naturally present in macular cells in the center of the human retina, absorbs blue and near-ultraviolet light radiation, thereby protecting the retinal cells against phototoxic damage. Zeaxanthin preparations which contain only the desired R--R isomer can be produced by a strain of Flavobacterium multivorum cells (ATCC accession number 55238). These cells (and other cells transformed with their zeaxanthin-producing genes) do not create any detectable quantities of the undesired S--S or S-R isomers of zeaxanthin, and they do not synthesize significant quantities of other carotenoids which might compete against zeaxanthin for alimentary uptake after oral ingestion. After synthesis using cell fermentation, the zeaxanthin can be concentrated to about 5-20% by simple and inexpensive steps such as solvent extraction, and can be purified to much higher levels by other methods if desired. The isomerically pure preparations can be taken orally, either as a therapeutic drug by patients suffering from macular degeneration, or as a nutritional supplement by anyone who wants to reduce his or her risk of suffering from age-related macular degeneration, which is widespread among people over the age of about 50 or 60.
REFERENCES:
patent: 3841967 (1974-10-01), Dasek et al.
patent: 3891504 (1975-06-01), Schocher et al.
patent: 3951743 (1976-04-01), Shepherd et al.
patent: 4153615 (1979-05-01), Saucy
patent: 4522743 (1985-06-01), Horn et al.
patent: 4726955 (1988-02-01), Horn et al.
patent: 4851339 (1989-07-01), Hills
patent: 4952716 (1990-08-01), Lukac et al.
patent: 5180747 (1993-01-01), Matsuda et al.
patent: 5227507 (1993-07-01), Lukac et al.
patent: 5308759 (1994-05-01), Gierhart
patent: 5310764 (1994-05-01), Baranowitz et al.
patent: 5350773 (1994-09-01), Schweikert et al.
patent: 5356636 (1994-10-01), Schneider et al.
patent: 5382714 (1995-01-01), Khachik
patent: 5427783 (1995-06-01), Gierhart
patent: 5429939 (1995-07-01), Misawa et al.
Bendich, A., et al, "Biological actions of carotenoids," FASEB Journal 3: 1927-1932 (1989).
Bone, R.A., et al, "Preliminary identification of the human macular pigment," Vision Res. 25: 1531-1535 (1985).
Bone R.A., et al, "Stereochemistry of the macular carotenoids," Invest. Ophthalmol. Vis. Sci. 34: 2033-2040 (1993).
Columbo, V.E., et al, "Structures and properties of stabilized vitamin and carotenoid dry powders," Food Structure 10: 161-170 (1991).
di Mascio, P., et al, "Lycopene as the most efficient biological carotenoid singlet oxygen quencher," Archives of Biochemistry and Biophysics 274: 532-538 (1989).
di Mascio, P., et al, "Antioxidant defense systems: the role of carotenoids, tocopherols, and thiols," Am. J. Clin. Nutr. 53: 194S-200S (1991).
Dorey, C.K., et al, "Lipofuscin in aged and AMD eyes," in Retinal Degeneration (Hollyfield et al, editors, Plenum Press, New York, 1993).
Eye Disease Case Control Study Group, "Antioxidant status and neovascular age-related macular degeneration," Arch. Ophthalmol. 11: 104-109 (1993).
Eye Disease Case Control Study Group, "Antioxidant status and neovascular age-related macular degeneration," Arch. Ophthalmol. 10: 1701-1708 (1992).
Haegerstrom-Portnoy, G., "Short-wavelength-sensitive-cone sensitivity loss with aging: a protective role for macular pigment?," J. Opt. Soc. Am. A5: 2140-2144 (1988).
Handelman, G.J. and Dratz, E.A., "The role of antioxidants in the retina and retinal pigment epithelium and the nature of prooxidant-induced damage," Adv. in Free Radical Biology & Medicine 2: 1-23 and 55-57 (1986).
Handelman, G.J., et al, "Carotenoids in the human macula and whole retina," Invest. Ophthalmol. Vis. Sci. 29: 850-855 (1988).
Malinow, M.R., et al, "Diet-related macular anomalies in monkeys," Invest. Ophthalmol. Vis. Sci. 19: 857-863 (1980).
National Advisory Eye Council, Vision Research Research: A National Plan, 1994-1998 (NIH Publication 93-3186), pp. 55-64, 336, and 356.
Seddon, J.M., et al, "Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration," JAMA 272: 1413-1420 (1994).
Sperduto, R.D., et al, "Do we have a nutritional treatment for age-related cataract or macular degeneration?," Arch. Ophthalmol. 108: 1403-1405 (1990).
Taylor, A., et al, "Oxidation and aging: impact on vision," Journal of Toxicology and Industrial Health 9: 349-371 (1993).
Garnett Kevin M.
Gierhart Dennis L.
Guerra-Santos Luis H.
Applied Food Biotechnology, Inc.
Kelly Patrick D.
Lilling Herbert J.
LandOfFree
Method of making pure 3R-3'R stereoisomer of zeaxanthin for huma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of making pure 3R-3'R stereoisomer of zeaxanthin for huma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of making pure 3R-3'R stereoisomer of zeaxanthin for huma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1423463